Gilead Sciences's most recent trend suggests a bearish bias. One trading opportunity on Gilead Sciences is a Bear Call Spread using a strike $74.50 short call and a strike $80.00 long call offers a potential 11.11% return on risk over the next 9 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $74.50 by expiration. The full premium credit of $0.55 would be kept by the premium seller. The risk of $4.95 would be incurred if the stock rose above the $80.00 long call strike price.
The 5-day moving average is moving down which suggests that the short-term momentum for Gilead Sciences is bearish and the probability of a decline in share price is higher if the stock starts trending.
The 20-day moving average is moving down which suggests that the medium-term momentum for Gilead Sciences is bearish.
The RSI indicator is at 58.29 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Gilead Sciences
New Data on Gilead’s Biktarvy® Presented at CROI 2020, Including Data in Black Americans and Older Adults
Mon, 09 Mar 2020 18:53:00 +0000
Gilead Sciences Inc. (Nasdaq: GILD) today announced data from the BRAAVE 2020 study, a Phase 3 clinical trial evaluating the safety and efficacy of switching to Biktarvy® (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg tablets, BIC/FTC/TAF) in virologically suppressed adults living with HIV who self-identified as Black or African American. The data show that, at 24 weeks, switching to Biktarvy from a standard regimen of two nucleoside reverse transcriptase inhibitors (NRTIs) plus a third agent may potentially be an effective and well-tolerated treatment regimen in patients with a history of treatment failure or pre-existing resistance, and did not result in treatment emergent resistance to study drugs with Biktarvy. The use of Biktarvy in individuals with a history of treatment failure or known resistance to the components of Biktarvy is investigational.
Two Companies Are Making Progress on Coronavirus Treatments. The Stocks Aren’t Responding.
Mon, 09 Mar 2020 18:48:00 +0000
Gilead Sciencesand Regeneron Pharmaceuticals are both making progress in developing treatments for coronavirus.
Stocks To Watch: Gilead Sciences Sees RS Rating Rise To 93
Mon, 09 Mar 2020 16:51:00 +0000
On Monday, Gilead Sciences received an upgrade to its Relative Strength (RS) Rating, from 90 to 93. When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.
High-Flying Gilead Slides Amid RBC Downgrade and Market Rout
Mon, 09 Mar 2020 16:01:00 +0000
While RBC notes it expects 'further upside' from Gilead, analysts at the firm are growing wary of the relatively high valuation of the drug development company's share price.
GSK's HIV combo treatment meets main goal in late-stage study
Mon, 09 Mar 2020 15:13:14 +0000
GlaxoSmithKline PLC's unit ViiV Healthcare said on Monday its two-drug regimen to treat HIV was as effective in patients given the treatment every two months, as when administered once a month. The drug, Cabenuva, the long-acting injectable two-drug regimen of antiviral compounds cabotegravir and Johnson & Johnson's rilpivirine, met the main goal at the end of 48 weeks. “This two-drug regimen may provide an opportunity for people living with HIV to break the cycle of taking a daily pill and reduce their total treatment dosing days from 365 to six,” Kimberly Smith, head of research and development, said.
Also on Market Tamer…
Follow Us on Facebook